Sotera Health earnings beat by $0.02, revenue topped estimates

Sotera Health (SHC) reported Q3 EPS of $0.29, beating estimates by $0.02, with revenue at $324.89M, topping expectations. The company provided FY 2026 guidance, with EPS and revenue estimates slightly below consensus. SHC's stock is down 5.94% over 3 months but up 7.97% year-over-year.

Original reporting
Published Nov 3, 2026, 1:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SHC
Bullish
medium confidence
Mentioned
$SHC
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SHCBullishMed
01

Why it matters

Traders can update near-term expectations using the beat and the FY26 guidance ranges, and reassess whether recent EPS revision momentum is improving or deteriorating.

02

Market read

Q3 beat plus FY26 guidance near consensus creates a tradable setup, but the lack of a large guidance surprise suggests more incremental than transformative repricing.

03

What to watch

The article notes 2 positive and 4 negative EPS revisions over 90 days, which could temper enthusiasm even after the quarter beat.

Relevance 8/10Novelty 8/10Timing: post-earnings, same-day digestion of Q3 results and FY26 guidance

Background

This is Sotera Health’s Q3 earnings report with explicit FY26 EPS and revenue guidance ranges versus analyst consensus.

Company-level read

Ticker impact

$SHCBullishMedium confidence
Context

Sotera Health reported Q3 EPS of $0.29, beating $0.27 consensus, and revenue of $324.89M versus $319.84M, plus FY26 EPS and revenue guidance.

Expected impact

Likely modest support as the market digests the beat and guidance, with follow-through dependent on how investors interpret the mix of EPS revisions.

Evidence & confidence

The article provides concrete Q3 results and FY26 guidance ranges versus consensus, but does not include margins, backlog, or a major surprise that would strongly reprice the stock.

Market effects

Adds incremental signal on managed care and healthcare services demand and cost discipline, but no sector-wide read-through is provided.

No specific regional linkage beyond US healthcare equities.

Primarily US-listed company earnings, with limited global spillover.

Counterpoint

The guidance is close to consensus, so the stock reaction may fade if investors were already positioned for a beat and focus shifts to forward margin or utilization trends not discussed here.

Key entities

  • Sotera Health

    NASDAQ-listed healthcare services company reporting Q3 results and FY26 guidance.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.